Grand Pharmaceutical GroupCGPHF 87 ROA % is 0.54% as of Dec. 2025, which is 94% below its 10-year median of 8.41. GuruFocus rates CGPHF with a GF Score™ of 87/100. The stock has 6 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Grand Pharmaceutical Group ranks better than 60.83% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Grand Pharmaceutical Group's annualizedNet Income for the quarter that ended in Dec. 2025 was $18.47 Mil.
Grand Pharmaceutical Group's average Total Assets over the quarter that ended in Dec. 2025 was $3,431.88 Mil. Therefore, Grand Pharmaceutical Group's annualized ROA % for the quarter that ended in Dec. 2025 was 0.54%.
The historical rank and industry rank for Grand Pharmaceutical Group's ROA % or its related term are showing as below:
CGPHF'
s ROA % Range Over the Past 10 Years
Min: 3.91 Med: 8.41 Max: 12.63
Current: 4.73
During the past 13 years, Grand Pharmaceutical Group's highest ROA % was 12.63%. The lowest was 3.91%. And the median was 8.41%.
CGPHF's ROA % is ranked better than 60.83% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs CGPHF: 4.73
Grand Pharmaceutical Group (OTCPK:CGPHF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grand Pharmaceutical Group's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Pharmaceutical Group ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grand Pharmaceutical Group's ROA % distribution charts can be found below:
* The bar in red indicates where Grand Pharmaceutical Group's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Grand Pharmaceutical Group (CGPHF) has a ROA % of 0.54% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Grand Pharmaceutical Group and its competitors. This is 94% below median its historical median of 8.41. Over the past decade, Grand Pharmaceutical Group's ROA % has ranged from 3.91 to 12.63. According to the industry distribution chart, Grand Pharmaceutical Group ranks #394 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 39.2%.
Is Grand Pharmaceutical Group's ROA % too high?
Grand Pharmaceutical Group's current ROA % of 0.54% is 94% below median its 10-year median of 8.41. Over the past 10 years, this metric has ranged from a low of 3.91 to a high of 12.63. The Drug Manufacturers industry median ROA % is 2.69. Grand Pharmaceutical Group's value of 0.54% is 79.9% below this industry median. Based on the distribution chart, Grand Pharmaceutical Group ranks #394 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grand Pharmaceutical Group has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Grand Pharmaceutical Group's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grand Pharmaceutical Group ranks #394 out of 1006 companies for ROA %. This puts Grand Pharmaceutical Group in the upper half of its industry. The industry median ROA % is 2.69. Grand Pharmaceutical Group's value of 0.54% is 79.9% below this benchmark. Historically, Grand Pharmaceutical Group's own ROA % has ranged from 3.91 to 12.63 over the past decade. While the company's 10-year median is 8.41 vs. the industry median of 2.69, Grand Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Pharmaceutical Group's current ROA % of 0.54% is 79.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Grand Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Pharmaceutical Group's current ROA % is 0.54%, which is 94% below median its own 10-year median of 8.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Pharmaceutical Group stock overvalued right now?
Grand Pharmaceutical Group (CGPHF) has a current ROA % of 0.54%. The current ROA % is 0.54%, which is 94% below median its 10-year median of 8.41 and 79.9% below the Drug Manufacturers industry median of 2.69. Grand Pharmaceutical Group's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Grand Pharmaceutical Group (CGPHF), the current ROA % is 0.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGPHF has been successfully added to your 